Brought to you by 
Genentech spin-out Genevax raises $18mm in Series A round
07 Apr 2016
Executive Summary
Genevax Inc., recently spun out by Genentech to develop its gp120 AIDS vaccine project, raised $18mm from venture capitalists in a Series A round. The new company will use the proceeds to fund Phase III development of a glycoprotein 120 AIDS vaccine it took over from Genentech, which will hold 25% of Genevax after the separate spin-out is complete.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech spin-out Genevax raises $18mm in Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice